Skip to content

AGADAGA Trial

A COMPARISON OF THE DURATION OF CERVICAL RIPENING WITH USE OF VAGINAL MISOPROSTOL PLUS HYOSCINE-N-BUTYLBROMIDE (HBB) TO VAGINAL MISOPROSTOL ALONE: A DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202112821475292
Enrollment
126
Registered
2021-12-22
Start date
2021-12-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Placebo
IM Hyoscine

Sponsors

Dr. Agadaga Ifeakachukwu Destiny
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: All consenting participants Singleton pregnancy Cephalic presentation Intact fetal membrane Gestational age greater or equal to 37 weeks Absence of spontaneous uterine contraction Bishop score less than or equal to 5 Reactive non stress test

Exclusion criteria

Exclusion criteria: Participant's refusal Multiple pregnancy Abnormal fetal presentation Ruptured fetal membrane Gestational age less than 37 weeks Presence of spontaneous uterine contraction Fetal congenital abnormality Intrauterine fetal death Previous uterine surgery Grandmultiparity Contraindication to vaginal delivery Abnormal non stress test Bishop score greater or equal to 6 Any known allergy to misoprostol and/or hyoscine

Design outcomes

Primary

MeasureTime frame
The cervical ripening time

Secondary

MeasureTime frame
Induction-delivery interval, oxytocin requirement, rate of vaginal and operative deliveries, Apgar scores at 1 and 5 minutes, admission into the neonatal unit, complications of cervical ripening and side effects hyoscine and/or misoprostol

Countries

Nigeria

Contacts

Public ContactIfeakachukwu Agadaga

Senior Registrar

agadest@gmail.com+2348068844035

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026